首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Plasma levels of pentraxin 3 in patients with spondyloarthritis
Authors:Renato Nisihara  Thelma L Skare  João Otávio Zeni  Henrique Rasera  Karita Lidani  Iara Messias-Reason
Institution:1. Department of Medicine, Positivo University, Curitiba, Paraná, Brazil;2. Immunopathology Molecular Laboratory, Clinical Hospital, Federal University of Paraná, Curitiba, Paraná, Brazil;3. Rheumatology Unit, Evangelical University, Curitiba, Paraná, Brazil;4. Immunopathology Molecular Laboratory, Clinical Hospital, Federal University of Paraná, Curitiba, Paraná, Brazil
Abstract:Context: Determining the disease’s inflammatory activity in spondyloarthritis (SpA) is difficult although very important as it is this that drives treatment.

Objective: To investigate if plasma pentraxin-3 (PTX3) could act as an inflammatory marker in SpA.

Methods: Eighty one SpA patients (11 with psoriatic arthritis (PsoA) and 70 with ankylosing spondylitis (AS)) and 90 gender and age paired controls were studied for plasma PTX3 levels by ELISA. Patients had determinations of disease activity through C reactive protein (CRP), erythrocyte sedimentation rate (ESR), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP. Epidemiological, clinical and treatment data were collected through chart review.

Results: SpA patients had lower concentrations of plasma PTX3 than controls (median of 0.95?ng/mL vs 1.64?ng/mL; p?p?=?0.42). Uveitis, presence of HLA B27, tobacco exposure, age and disease duration did not influence PTX3 levels.

Conclusions: PTX3 plasma levels do not reflect disease activity in SpA. However, it probably participates in the ethiopathogenetic process, as it is consumed in these patients.
Keywords:Spondyloarthritis  biomarker  disease activity  inflammation  pentraxin 3
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号